RxDoctor Payments Data

Angelina Lombardi, MD

Allergy · Greenville, SCNPI 1487645107

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 232 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 27 manufacturers reported payments, led by Sanofi at 27.0% of the total.

$3,931in general payments, 2019–2025

Across 232 payments — averaging $16.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$1K
  • AstraZeneca$600
  • CSL Behring$431
  • GSK$328
  • Hospira, Inc.$308
  • Genentech USA, Inc.$128
  • plus $1K from 21 others

What the payments were for

  • Food & beverage$3,931100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few allergy providers in South Carolinato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$120,801
Medicare patients
166
Services billed
5,583

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XolairOmalizumab12$44,018
Trelegy ElliptaFluticasone/Umeclidin/Vilanter41$28,357
Breztri AerosphereBudesonide/Glycopyr/Formoterol22$20,748
Breo ElliptaFluticasone/Vilanterol15$6,800
Desloratadine88$3,160
Epinephrine15$3,043
Albuterol Sulfate HfaAlbuterol Sulfate59$2,382
Wixela InhubFluticasone Propion/Salmeterol11$2,081
Fluticasone-SalmeterolFluticasone Propion/Salmeterol15$2,003
Levocetirizine Dihydrochloride68$1,331
Fluticasone Propionate44$821
Azelastine Hcl19$488
Hydroxyzine Hcl17$427
Montelukast Sodium41$410
Fluconazole12$77

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Genentech, Inc.Xolair$27$44,01812 claims
GSKTrelegy Ellipta, Breo Ellipta$328$35,15756 claims
AstraZenecaBreztri Aerosphere$600$20,74822 claims
Hikma Pharmaceuticals USAEpinephrine$30$3,04315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few allergy providers in South Carolinaon file to place this against a meaningful peer group, so we don't.

Other allergy in Greenville

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →